{"id":16847,"date":"2023-10-31T10:10:56","date_gmt":"2023-10-31T10:10:56","guid":{"rendered":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/"},"modified":"2023-11-03T11:46:10","modified_gmt":"2023-11-03T11:46:10","slug":"pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p","status":"publish","type":"the-bmj-article","link":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/","title":{"rendered":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer"},"featured_media":0,"template":"","categories":[],"tags":[],"content_type":[36],"editorial_panel":[],"channel_page":[44],"class_list":["post-16847","the-bmj-article","type-the-bmj-article","status-publish","hentry","article-type-research","channel-page-research"],"aioseo_notices":[],"meta_box":{"the_bmj_article-url":"\/content\/383\/bmj-2023-076065","the_bmj_article-description":"Pyrotinib plus trastuzumab and docetaxel improved progression-free survival versus placebo with trastuzumab and docetaxel, finds study","the_bmj_article-the_bmj_article_image":[{"width":150,"height":150,"file":"2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage.png","filesize":48623,"sizes":{"medium":{"file":"Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage-300x194.png","width":300,"height":194,"mime-type":"image\/png","filesize":20928,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage-300x194.png"},"thumbnail":{"file":"Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage-150x150.png","width":150,"height":150,"mime-type":"image\/png","filesize":8522,"url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage-150x150.png"}},"image_meta":{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0","keywords":[]},"ID":"16852","name":"Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage.png","path":"\/dom34810\/wp-content\/uploads\/sites\/4\/2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage.png","url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage-150x150.png","full_url":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-content\/uploads\/sites\/4\/2023\/10\/Breast-Cancer-Pyrotinib-Visual-Abstract-Homepage.png","title":"Breast Cancer Pyrotinib Visual Abstract - Homepage","caption":"","description":"","alt":"Breast Cancer Pyrotinib Visual Abstract - Homepage","srcset":false}],"the_bmj_article-related_articles":[{"article_type":"","related_article_title":"","related_article_url":""}],"the_bmj_article-journal_name":""},"head_tags":[{"tag":"title","content":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer | The BMJ"},{"tag":"meta","attributes":{"name":"robots","content":"max-image-preview:large"}},{"tag":"link","attributes":{"rel":"canonical","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/"}},{"tag":"meta","attributes":{"name":"generator","content":"All in One SEO (AIOSEO) 4.9.6.2"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ | The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:title","content":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer | The BMJ"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/"}},{"tag":"meta","attributes":{"property":"article:published_time","content":"2023-10-31T10:10:56+00:00"}},{"tag":"meta","attributes":{"property":"article:modified_time","content":"2023-11-03T11:46:10+00:00"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer | The BMJ"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","type":"application\/rss+xml","title":"The BMJ \u00bb Comments Feed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/comments\/feed\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (JSON)","type":"application\/json+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fpyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p%2F"}},{"tag":"link","attributes":{"rel":"alternate","title":"oEmbed (XML)","type":"text\/xml+oembed","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/oembed\/1.0\/embed?url=https%3A%2F%2Fbmj-chicken.bmj.com%2Fthebmj%2Fthe-bmj-article%2Fpyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p%2F&format=xml"}},{"tag":"link","attributes":{"rel":"https:\/\/api.w.org\/","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/"}},{"tag":"link","attributes":{"rel":"alternate","title":"JSON","type":"application\/json","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/16847"}},{"tag":"link","attributes":{"rel":"EditURI","type":"application\/rsd+xml","title":"RSD","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/xmlrpc.php?rsd"}},{"tag":"meta","attributes":{"name":"generator","content":"WordPress 6.9.4"}},{"tag":"link","attributes":{"rel":"shortlink","href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/?p=16847"}},{"tag":"meta","attributes":{"property":"og:locale","content":"en_GB"}},{"tag":"meta","attributes":{"property":"og:site_name","content":"The BMJ"}},{"tag":"meta","attributes":{"property":"og:title","content":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer"}},{"tag":"meta","attributes":{"property":"og:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/"}},{"tag":"meta","attributes":{"property":"og:type","content":"article"}},{"tag":"meta","attributes":{"property":"og:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:title","content":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel in patients with HER2 positive metastatic breast cancer"}},{"tag":"meta","attributes":{"name":"twitter:url","content":"https:\/\/bmj-chicken.bmj.com\/thebmj\/the-bmj-article\/pyrotinib-versus-placebo-in-combination-with-trastuzumab-and-docetaxel-as-first-line-treatment-in-patients-with-her2-positive-metastatic-breast-cancer-phila-randomised-double-blind-multicentre-p\/"}},{"tag":"meta","attributes":{"name":"twitter:description","content":"The BMJ: leading general medical journal. Research. Education. Comment"}},{"tag":"meta","attributes":{"name":"twitter:card","content":"summary_large_image"}}],"_links":{"self":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article\/16847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/the-bmj-article"}],"about":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"type":[{"embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/types\/the-bmj-article"}],"wp:attachment":[{"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/media?parent=16847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/categories?post=16847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/tags?post=16847"},{"taxonomy":"article-type","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/content_type?post=16847"},{"taxonomy":"editorial-panel","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/editorial_panel?post=16847"},{"taxonomy":"channel-page","embeddable":true,"href":"https:\/\/bmj-chicken.bmj.com\/thebmj\/wp-json\/wp\/v2\/channel_page?post=16847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}